Optimizing treatment in social phobia: a review of treatment resistance. (Q35901880)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15448580 AND SRC:MED&resulttype=core&format=json

3 January 2020

review article

1 reference

title

Optimizing treatment in social phobia: a review of treatment resistance (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15448580 AND SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Michael Van Ameringen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15448580 AND SRC:MED&resulttype=core&format=json

3 January 2020

Catherine Mancini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15448580 AND SRC:MED&resulttype=core&format=json

3 January 2020

Beth Pipe

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15448580 AND SRC:MED&resulttype=core&format=json

3 January 2020

Mark Bennett

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15448580 AND SRC:MED&resulttype=core&format=json

3 January 2020

publication date

1 October 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15448580 AND SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15448580 AND SRC:MED&resulttype=core&format=json

3 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15448580 AND SRC:MED&resulttype=core&format=json

3 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15448580 AND SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

753-762

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15448580 AND SRC:MED&resulttype=core&format=json

Treatment of social phobia with the dopamine agonist pergolide

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Efficacy of olanzapine in social anxiety disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Usefulness of olanzapine in refractory panic attacks.

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Olanzapine in the treatment of post-traumatic stress disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Valproate in the treatment of acute mania. A placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Capsulotomy for refractory anxiety disorders: long-term follow-up of 26 patients

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Behavior therapy of phobias: predictors of outcome

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Exposure in vivo vs social skills training for social phobia: long-term outcome and differential effects

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

The role of atypical antipsychotics in bipolar depression and anxiety disorders

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Personality disorders and time to remission in generalized anxiety disorder, social phobia, and panic disorder

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Predictors of response in generalized social phobia: effect of age of onset

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Implications of the severity of social phobia

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

A 2-year follow-up of social phobia. Status after a brief medication trial

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Long-term outcome of social phobia treated by exposure

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Pharmacotherapy of social anxiety disorder: an algorithm for primary care 2001

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Impact of generalized social anxiety disorder in managed care

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

The role of the sympathetic nervous system in anxiety: Is it possible to relieve anxiety with endoscopic sympathetic block?

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Cognitive-behavioral therapy for social anxiety disorder: current status and future directions

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

The influence on treatment gain of comorbid avoidant personality disorder in patients with social phobia

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Phenelzine efficacy in refractory social anxiety disorder: a case series

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Treatment of social phobia with gabapentin: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Predictors of Response to Cognitive-Behavioral Group Therapy for Social Phobia

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Diagnosis and definition of treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Paroxetine in social anxiety disorder: a randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Social phobia: long-term treatment outcome and prediction of response--a moclobemide study

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Prediction of treatment outcome in social phobia: a cross-validation

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale.

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

The Boundary of Social Phobia

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Treatment of social phobia with clonazepam and placebo.

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials.

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Clinical features affecting treatment outcome in social phobia

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

The economic consequences of social phobia

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Neurobiological mechanisms of social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

A Comparison of the Efficacy of Clonazepam and Cognitive-Behavioral Group Therapy for the Treatment of Social Phobia

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Disability and quality of life in pure and comorbid social phobia. Findings from a controlled study.

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Sertraline for social phobia: a double-blind, placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Pharmacological treatment of social anxiety disorder: a meta-analysis

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

The impact of anxiety disorders on educational achievement

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study

1 reference

https://api.crossref.org/works/10.1017/S1092852950022392

7 January 2021

10.1017/S1092852950022392

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15448580 AND SRC:MED&resulttype=core&format=json

3 January 2020

1 reference